Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung …

JB Auliac, C Chouaid, L Greiller, I Monnet, H Le Caer… - Lung cancer, 2014 - Elsevier
Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …
被引用次数：26 相关文章

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung …

JB Auliac, C Chouaid, L Greillier, I Monnet… - Lung Cancer …, 2014 - europepmc.org
Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung …

JB Auliac, C Chouaid, L Greiller, I Monnet, H Le Caer… - Lung Cancer, 2014 - infona.pl
Concomitant administration of erlotinib with standard chemotherapy does not appear to
improve survival among patients with non-small-cell lung cancer (NSCLC), but preliminary …

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung …

JB Auliac, C Chouaid, L Greillier, I Monnet, H Le Caer… - 2014 - pubmed.ncbi.nlm.nih.gov
Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …

[引用][C] Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell …

JB AULIAC, C CHOUAID, R SCHOTT, A BIZIEUX… - Lung …, 2014 - pascal-francis.inist.fr
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib
and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after …

[引用][C] Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell …

JB Auliac, C Chouaid, L Greiller, I Monnet, H Le Caer… - Lung Cancer, 2014 - cir.nii.ac.jp
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and
docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of …
[PDF] academia.edu

[PDF][PDF] Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell …

JB Auliac, C Chouaid, L Greiller, I Monnet, H Le Caer… - Lung …, 2014 - academia.edu
abstract Background: Concomitant administration of erlotinib with standard chemotherapy
does not appear to improve survival among patients with non-small-cell lung cancer …

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung …

JB Auliac, C Chouaid, L Greiller, I Monnet… - Lung …, 2014 - lungcancerjournal.info
Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …

[引用][C] Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell …

JB AULIAC, C CHOUAID, L GREILLER, I MONNET… - Lung cancer, 2014 - Elsevier